
Sign up to save your podcasts
Or
Moderator: James P. Rathmell, M.D. Participants: Rebecca L. Wu, M.D. and Max B. Kelz, M.D., Ph.D. Articles Discussed: TAK-925 (danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-Induced Respiratory Depression and Sedation Without Affecting Analgesia in Healthy Adult Males Alluring Potential to Accelerate Emergence and Ameliorate Opioid-induced Respiratory Depression without Antagonizing Analgesia: Danavorexton Enters the Anesthetic Landscape Transcript
4.2
4444 ratings
Moderator: James P. Rathmell, M.D. Participants: Rebecca L. Wu, M.D. and Max B. Kelz, M.D., Ph.D. Articles Discussed: TAK-925 (danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-Induced Respiratory Depression and Sedation Without Affecting Analgesia in Healthy Adult Males Alluring Potential to Accelerate Emergence and Ameliorate Opioid-induced Respiratory Depression without Antagonizing Analgesia: Danavorexton Enters the Anesthetic Landscape Transcript
129 Listeners
83 Listeners
1,868 Listeners
314 Listeners
488 Listeners
1,446 Listeners
83 Listeners
1,090 Listeners
184 Listeners
277 Listeners
411 Listeners
246 Listeners
18 Listeners
23 Listeners
214 Listeners